top of page
NEW_ESM_Bruges24_banner.jpg

Delegate Resources

These resources are for ESM Congress delegates only.

Please do not share.

Abstracts

GL08

Invited speaker

Unlocking the potential of phylodynamic birth-death models: Opportunities and challenges in TB epidemiology

Etthel Windels, ETH Zürich, Basel

GL12

Invited speaker

BNT164: Preclinical development of two mRNA-based tuberculosis vaccine candidates

Stefan Schille, Immunotherapies and Preclinical Research, BioNTech SE, 55131 Mainz

GL15

Invited speaker

Tackling the Tip of the Iceberg – Using a One Health Approach to Tuberculosis

Michele A Miller, Stellenbosch University, Faculty of Medicine and Health Sciences

GL16

Invited speaker

One health approaches to trace M. leprae's zoonotic potential through time

Verena Schuenemann, University of Basel

GL18

Invited speaker

The (re)discovery of the spectrum of TB

Rein Houben, London School of Hygiene and Tropical Medicine

GL19

Invited speaker

Genomic studies of tuberculosis in archaeological bone

Kirsten Bos, Max Planck Institute for Evolutionary Anthropology

GL21

Invited speaker

Single nucleotide variation catalogue from clinical isolates mapped on tertiary and quaternary structures of ESX-1–related proteins reveal critical regions as putative Mtb therapeutic targets

Oren Tzfadia, Institute of Tropical Medicine

GL22

Invited speaker

Data-driven assessment of Mycobacterium tuberculosis transmission in evolving demographic structures

Joaquín Sanz, Institute for Bio-computation and Physics of Complex Systems (BIFI), University of Zaragoza, Zaragoza

OR01

Non-tuberculous mycobacteria

A novel, high-content imaging based approach towards antibiotic drug discovery for non-tuberculous mycobacteria

Winston Chiu, KU Leuven

OR02

Diagnostics

GPAS: evaluation of mycobacterial species identification of 7798 MGIT samples

Tim Peto, University of Oxford

OR03

TB treatment

Towards restoring antibiotic sensitivity in Mycobacterium tuberculosis using bacteriophages

Joanna Evans, The Francis Crick Institute

OR04

TB treatment

Safety of high-dose amikacin in the first week of all-oral rifampicin-resistant tuberculosis treatment for the prevention of acquired resistance

Jihad Snobre, Institute of Tropical Medicine Antwerpen

OR05

Diagnostics

Point-of-care lung ultrasound for the detection of pulmonary tuberculosis in Benin: the TrUST study

Veronique Suttels, Lausanne University Hospital, dpt of infectious diseases, Lausanne, Switzerland

OR06

Other

Use of a modified face mask and liquid-based cough aerosol sampling system to measure the infectiousness of drug-resistant tuberculosis patients

Rouxjeane Venter, DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, SA MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa

OR07

Diagnostics

Pluslife MTBC Card: a new rapid diagnostic tool for management of pulmunary TB patients

Francesco Bisognin, Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy

OR08

Diagnostics

Routine whole genome sequencing of Mycobacterium tuberculosis when the consensus in not enough

Richard Anthony, RIVM National Tuberculosis Reference Laboratory, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands

OR09

Omics and modelling

Genomic epidemiology of tuberculosis using long-read sequencing to increase resolution of transmission clusters

Ana Maria Garcia-Marin, Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, 46010, Spain

OR10

Host pathogen and vaccines

Conservation of M72/​AS01E vaccine epitopes in 31,428 Mycobacterium tuberculosis isolates

Klaas Dewaele, Institute of Tropical Medicine Antwerp

OR11

Host pathogen and vaccines

Deciphering Tuberculosis host-pathogen coevolution using Drosophila melanogaster as a model system

Marta Arch, Germans Trias i Pujol Research Institute (IGTP)

OR12

Other

Host and Pathogen Determinants of TB Disease and Transmission in TanzaniaHost and Pathogen Determinants of TB Disease and Transmission in Tanzania

Daniela Brites, Swiss Tropical and Public Health Institute

OR13

Diagnostics

Sex and progression towards active TB in an experimental mouse model. Impact of stress-induced glucocorticoids and intermittent fasting

Pablo Soldevilla, Unitat de Tuberculosi Experimental, Microbiology Dept. Germans Trias i Pujol Research Institute and Hospital (IGTP-HUGTIP), Badalona, 08916, Spain

OR14

Host pathogen and vaccines

Unraveling host-specific in vitro virulence profiles of Mycobacterium tuberculosis ecotypes

Marta Caballer Gual, Universidad de València

OR15

Other

Inhibition of menaquinone biosynthesis results in re-sensitization of Bedaquiline resistant Mycobacterium tuberculosis

Jennefer Wetzel, Johnson and Johnson Innovative Medicine - Global Public Health

OR16

One health

In vitro host gene expression profiles in cross-infections of Mycobacterium tuberculosis ecotypes

Mireia Coscolla, Institute for integrative systems biology

OR17

One health

Democratizing education and research for new generation of medical professionals: TB Portals data and resources

Andrei Gabrielian,

OR18

Diagnostics

Reproducible algorithmic generation of resistance catalogues improves resistance prediction for bedaquiline in M. tuberculosis

Dylan Adlard, University of Oxford

OR19

TB treatment

Remission cytochrome spectroscopy reveals the mode of action of bedaquiline in living mycobacteria

Morwan Osman, University of York

OR20

Diagnostics

Nationwide evaluation of Xpert MTB/RIF Ultra reveals challenges in accurate diagnosis of rifampicin-resistant tuberculosis.

Isabel Cuella Martin, Institute of Tropical Medicine Antwerp

OR21

Diagnostics

Closing the diagnostic gap for the BPaLM treatment regimen with tNGS: Deeplex Myc-TB XL

Philip Supply, Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France

OR22

Omics and modelling

Unveiling the Drivers of Mycobacterium tuberculosis Lineage 2 success: An Integrative Approach

Thierry Wirth, Ecole Pratiques des Hautes Etudes, Paris, France

OR23

Other

Delving deeper into the evolution of drug resistance

Álvaro Chiner Oms, FISABIO-Public Health

OR24

One health

First evidence of pyrazinamide-susceptible Mycobacterium bovis, sub-lineage La1.1, in Ireland

Emma Roycroft, Irish Mycobacteria Reference Laboratory

OR25

Omics and modelling

Mycobacterium tuberculosis (Mtb) transcriptional adaptations to growth arrest: unveiling the role of iron and carbon sources

Jorge Alberto Cárdenas Pestana, Universidad de Zaragoza

OR26

Drug susceptibility testing

Rifampicin tolerance in Mycobacterium tuberculosis complex strains

Annemarie Hintz-Rüter, Reseach Center Borstel

OR27

Non-tuberculous mycobacteria

Spatial dual host-bacterial gene expression to study pathogenesis and the regulation of virulence factors in tissue during NTM respiratory infections

Federico Di Marco, San Raffaele Scientific Institute

OR28

TB treatment

Drivers of levofloxacin resistance in a high MDR-TB incidence country

Ori Solomon, McGill University

OR29

Drug susceptibility testing

Using long term evolution models to define drug resistance mechanisms to DDU209, a novel tuberculosis drug candidate

Lindsay Sonnenkalb, Research Center Borstel Leibniz Lung Centre

OR30

Omics and modelling

Improving the benchmark of Mycobacterium tuberculosis variant calling protocols with in silico evolved genomes

Guislaine Refrégier, Université Paris - Saclay

OR31

Diagnostics

Mutator genotypes drive resistance to antibiotics in natural isolates of Mycobacterium tuberculosis

Rima Zein Eddine, Laboratory for Optics and Biosciences (LOB), École Polytechnique (l’X, Palaiseau), France

P001

Other

Unrestrained long-chain fatty acid catabolism kills Mycobacterium tuberculosis

Tiago Beites, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto

P002

TB treatment

Insights into the use of cytochrome Bc inhibitors for future therapeutic strategies for tuberculosis

Clara Aguilar Perez, Johnson & Johnson Innovative Medicines

P003

Other

X-ray-based 3D histology of the human tongue and its coating using contrast-enhanced microCT imaging

Melanie Grobbelaar, Faculty of Medicine and Health Sciences, Stellenbosch University

P004

Non-tuberculous mycobacteria

M&Ms | The dependence of bacterial growth phase on Mycobacterium-Macrophage interaction

Tania Silva, i3S – Instituto de Investigação e Inovação e Saúde, Universidade do Porto

P005

Diagnostics

Enhancing tuberculosis diagnosis with a mathematical model integrating molecular test histories and patient-specific factors

Onya Opota, Institute of Microbiology, Lausanne University and University Hospital of Lausanne, Lausanne, Switzerland

P006

Drug susceptibility testing

Identification of Mycobacteroides abscessus complex subspecies and molecular determination of resistance to clarithromycin and amikacin

Fanourios Kontos, Laboratory of Clinical Microbiology, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

P007

Drug susceptibility testing

Subspecies distribution, and antibiotic susceptibility of Mycobacteroides abscessus complex isolates

Fanourios Kontos, Laboratory of Clinical Microbiology, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

P008

Drug susceptibility testing

Mycobacterial carbonic anhydrases as targets for tuberculosis research

Jenny Parkkinen, Tampere University

P009

Drug susceptibility testing

Applying whole genome sequencing to predict phenotypic drug resistance in Mycobacterium tuberculosis? Leveraging 20 years of nationwide data from Denmark

Mads Lindholm Kurtzhals, Statens Serum Institut

P010

TB treatment

Pharmaco-toxicological profile of sulfonyl hydrazone derivatives with potent antimycobacterial activity

Violina Angelova - Stoyanova, Medical University of Sofia

P011

TB treatment

Defining genetic interdependencies essential for M. tuberculosis survival

Valwynne Faulkner, The Francis Crick Institute

P012

Omics and modelling

Strain Resolution Revolution: Phylogenetic Reconstruction and Rapid SNP Assay Development for Mycobacterium bovis in Ireland

Ryan Magee, Queen's University Belfast

P013

Non-tuberculous mycobacteria

Combined use of commercial and sequencing analysis methods for the identification of non-tuberculous mycobacteria in a tertiary Hospital of Athens: Seventeen years of experience 

Fanourios Kontos, Laboratory of Clinical Microbiology, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

P015

Other

Simplified strategy to update tuberculosis transmission situation in Madrid by rationalizing molecular and genomic sequential analysis

Cristina Rodríguez-Grande, Instituto de Investigación Sanitaria Gregorio Marañón

P017

Omics and modelling

Overcoming H37Rv bias: a k-mer based approach to isolate-specific masking

Daniel Whiley, School of Science and Technology, Nottingham Trent University, Nottingham, UK

P018

Drug susceptibility testing

Genotypic and phenotypic drug susceptibility testing (DST) for Bedaquiline, Delamanid and Pretomanid in South-East Asian multi-drug resistant TB (MDR-TB) isolates

Tai Lee Kee, Singapore General Hospital

P019

Non-tuberculous mycobacteria

A M. abscessus tenosenovitis case: a diagnostic odyssey

Taeyang Chin, General Hospital Sint-Jan Brugge

P020

Non-tuberculous mycobacteria

NTM detection in a culture negative skin biopsy using bacterial sequencing: a case report

Taeyang Chin, General Hospital Sint-Jan Brugge

P021

Non-tuberculous mycobacteria

Genomic analysis of a Mycobacterium intracellulare subsp. chimaera variant cluster in a German hospital

Margo Diricks, Molecular and Experimental Mycobacteriology, Research Center Borstel, Leibniz Lung Center, Borstel, 23845, Germany

P022

TB treatment

The effect of diabetes mellitus on mortality during rifampicin-resistant tuberculosis treatment in Indonesia: a retrospective cohort study

Lara Veeken, Radboud University Medical Center

P023

Non-tuberculous mycobacteria

Characterization of a putative cobalt transport system in Mycobacterium smegmatis

Elke Goethe, University of Veterinary Medicine Hannover

P024

Omics and modelling

Illustrating variations in resistance mechanisms of Mycobacterium tuberculosis against bedaquiline

Teresa Walz, Research Center Borstel

P025

Non-tuberculous mycobacteria

In vitro activity of epetraborole, a novel LeuRS inhibitor, alone and in combination against rapidly growing non-tuberculous mycobacteria

Michael Cynamon, Veterans Health Research Institute, Syracuse, NY 13210, USA

P026

Omics and modelling

Tracking cross-border transmission of the Rwanda MDR-TB R3clone

Conor Meehan, Nottingham Trent University, Nottingham, UK

P027

Host pathogen and vaccines

Using the SpyTag/SpyCatcher system to determine the path of substrates through the mycobacterial type VII secretion system

Yuwei Ding, Section Molecular Microbiology, Amsterdam Institute for Life and Environment (A-Life), Vrije Universiteit, Amsterdam, The Netherlands

P028

Drug susceptibility testing

Expanding resources for bedaquiline resistance detection: generating heteroresistant mixtures for BCCM/ITM inclusion

Anzaan Dippenaar, Institute of Tropical Medicine, Antwerp

P030

Omics and modelling

Detection a new Mycobacterium tuberculosis complex modern L2  taxon based on SNPs in the Rv2983 and fgd1 gene

Christophe Sola, Inserm, IAME, UMR1137, Université Paris Cité

P031

Omics and modelling

Genetic Diversity and Drug Resistance Profiles of Mycobacterium tuberculosis L2/Beijing Isolates in Kazakhstan: Insights from Whole-Genome Sequencing

Pavel Tarlykov, National Center for Biotechnology

P032

Non-tuberculous mycobacteria

Almost half of the newly described Mycobacterium species are published with synonymous genus names

Leen Rigouts, Institute of Tropical Medicine

P033

Drug susceptibility testing

Limited phenotypic resistance for African clinical Mycobacterium tuberculosis isolates harboring variants in genes relevant for bedaquiline and delamanid resistance

Leen Rigouts, Laboratoire de Référence de Mycobactéries

P034

Host pathogen and vaccines

Cerebrospinal fluid fatty acid metabolism and tuberculous meningitis mortality

Arjan van Laarhoven, Radboudumc Community for Infectious Diseases, Nijmegen, the Netherlands

P035

Omics and modelling

Predominant clones of Mycobacterium tuberculosis in Sub-Saharan African Countries

Faridath Massou, Laboratoire de Référence des Mycobactéries, Cotonou, Benin

P036

Omics and modelling

Endemic transmission of Mycobacterium tuberculosis sublineage Beijing L2.2.M3 within Colon, Panama: A prospective study

Fermin Acosta, Centro de Biología Celular y Molecular de Enfermedades, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología de Panamá, Ciudad del Saber, Panamá.

P037

Host pathogen and vaccines

Transcriptomic Insights into Human Macrophage Responses to Mycobacterium tuberculosis Complex (MTBC) Strains

Jana Schoenfeld, Molecular and Experimental Mycobacteriology, Research Center Borstel Leibniz Lung Center

P038

Non-tuberculous mycobacteria

Non-tuberculous and tuberculous mycobacteria prevalence and drug susceptibility in Italian and foreign subjects: a monocentric observational study

Sara Caldrer, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella (Verona), Italy

P039

Other

Genomic insights into TB transmission networks: unveiling diagnostic delays or subclinical cases and their impact on secondary cases

Laura Pérez, Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain

P040

One health

Healthcare Workers and Migrants User Experience with Targeted Education Materials for Self Swabbing for TB Screening

Renee Codsi, Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, WA, USA

P041

Non-tuberculous mycobacteria

Transmission patterns of Mycobacterium leprae in the Comoros

Sofie Braet, University of Antwerp

P042

TB treatment

Influence of external potassium on the rifampicin susceptibility of Mycobacterium

Vijay Srinivasan, Theoretical Microbial Ecology Group, Institute of Microbiology, Faculty of Biological Sciences, Friedrich Schiller University Jena, Jena, Germany

P043

Drug susceptibility testing

LiquidArray® technology for the detection of extended drug resistance mutations

Viktoria Szel, National Reference Laboratory for Mycobacteriology, Hungary

P044

Non-tuberculous mycobacteria

Mycothione reductase as a potential target in the fight against Mycobacterium abscessus infections

Linda De Vooght, University of Antwerp

P045

Host pathogen and vaccines

Impact of ageing on the immunotherapy effect of mycobacteria against cancer

Esther Julian, Universitat Autònoma de Barcelona

P046

Omics and modelling

Machine learning approaches for the analysis of electrical signals from Oxford Nanopore Technologies to detect pharmaco-resistance in Mycobacterium tuberculosis

Alma Zinola, San Raffaele Scientific Institute

P047

TB treatment

Intrabacterial drug metabolism in Mycobacterium tuberculosis

Valerie Maes, KU Leuven

P048

Omics and modelling

Are there blaC alleles out there that would naturally confer resistance to clavulanic acid?

Dylan Dissanayake, University of Oxford

P049

Other

The hidden diversity of Mycobacterium tuberculosis complex in Africa: the new L10 and the possible diversification histories of the complex

Guislaine Refrégier, Université Paris-Saclay

P050

Host pathogen and vaccines

Comparative study of two deleted Mycobacterium bovis strains in experimental animal models

Ximena Ferrara, Instituto de Agrobiotecnología y Biotecnología Molecular (IABIMO), UEDD INTA-CONICET; CICVyA, Instituto Nacional de Tecnología Agropecuaria

P052

TB treatment

Treating flies: Drosophila melanogaster for screening new therapies against tuberculosis

Maria Vidal Ramos, Unitat de Tuberculosi Experimental, Microbiology Dept. Germans Trias i Pujol Research Institute and Hospital (IGTP-HUGTIP), Badalona, 08916, Spain

P054

Drug susceptibility testing

Performance of open-access genomic drug resistance prediction tools for Mycobacterium tuberculosis: a systematic review and meta-analysis

Klaas Dewaele, KU Leuven

P055

One health

Two cases of Mycobacterium microti among primates in a zoo facility

Dorte Bek Folkvardsen, International Reference Laboratory of Mycobacteriology, Statens Serum Institut

P056

Other

The effect of inhA promoter mutation on iron distribution in Mycobacterium tuberculosis

Marisa Klopper, Stellenbosch University

P057

Non-tuberculous mycobacteria

Oral administration of heat-killed Mycobacterium manresensis induces an increased response against subsequent infections in the Drosophila melanogaster model

Mariona Cortacans, Experimental Tuberculosis Unit (UTE), Institut de Recerca Germans Trias i Pujol (IGTP), Badalona (08916), Spain

P058

Drug susceptibility testing

Epidemiology, genetic diversity and drug susceptibility patterns by whole genome sequencing of Mycobacterium tuberculosis complex isolates in Gabon from 2012 to 2022

Viola Dreyer, Molecular and Experimental Mycobacteriology, Research Center Borstel - Leibniz Lung Center

P059

Other

Whole Genome Sequencing Analysis Reveals Interregional Transmission Dynamics of Tuberculosis in Spain: A Study of Catalonia and the Valencian Community

Iñaki Comas, Instituto de Biomedicina de Valencia, IBV-CSIC

P060

Other

Serratia sp. dominates the lung microbiome of patients with tuberculosis and non-tuberculous mycobacterial lung diseases

Meriem Belheouane, Research Center Borstel, Borstel

P061

Non-tuberculous mycobacteria

Diversity of nontuberculous mycobacteria in food animals: implications for food safety and one health

Gloria Ivy Mensah, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon/Accra, Ghana

P062

Drug susceptibility testing

A 3D-printed device for reproducible imaging of 96-well broth microdilution plates

Klaas Dewaele, Institute of Tropical Medicine Antwerp

P063

Drug susceptibility testing

Practical implementation of the WHO 2nd edition mutation catalogue in genotypic drug resistance detection pipelines

Jody Phelan, London School of Hygiene and Tropical Medicine

P064

Other

Population structure and transmission analysis of drug-resistant Mycobacterium tuberculosis´complex strains from Namibia based on whole genome sequencing

Olga Shavuka, University of Namibia School of Medicine.

P065

Other

Integrating genomic surveillance for tuberculosis control in Catalonia

Pere-Joan Cardona, Microbiology Department, Laboratori Clínic Metropolitana Nord. Institut de Recerca i Hospital Germans Trias i Pujol (IGTP) – Badalona, Catalonia (Spain) / CIBER in Respiratory Diseases (CIBERES) – Madrid (Spain) / Departament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, Catalonia (Spain)

P066

Host pathogen and vaccines

Establishing a 3D cell culture model of the tuberculosis granuloma as a drug-discovery platform

David Pires, Center for Interdisciplinary Research in Health, Católica Medical School, Universidade Católica Portuguesa, Rio de Mouro, 2635-631, Portugal.

P067

Drug susceptibility testing

Drug resistance patterns in pulmonary tuberculosis patients in Namibia based on targeted Next Generation Sequencing

Lusia Mhuulu, Department of Human, Biological & Translational Sciences, School of Medicine, University of Namibia, Namibia

P068

Omics and modelling

Exploring the adaptative landscape and factors impacting the epidemic success of Mycobacterium tuberculosis lineage 2 using simulations and genomic analyses

Nour Gharbi, EPHE, PSL University, Paris, France

P069

Omics and modelling

Nationwide temporal whole-genome sequencing analysis reveals high rates of clustering among multi-drug resistant Mycobacterium tuberculosis strains in South Africa

Christoph Wippel, Harvard Medical School

P070

TB treatment

Understanding pathways to chronic disease management for patients with tuberculosis in Haiti: A qualitative study

Joshua Ellis, Harvard Medical School

P071

Omics and modelling

TB Portals and the Quest for the Universal Reference Dataset.

Andrei Gabrielian, National Institute of Allergy and Infectious Diseases

P072

Drug susceptibility testing

Equivalent MIC results are observed by EUCAST BMD and MGIT for levofloxacin, moxifloxacin, D- cycloserine and linezolid

Manzour H Hazbón, BD

P073

Omics and modelling

UShER for Mycobacterium tuberculosis: an evaluation of pandemic-scale tools capacity to perform transmission surveillance

Francisco José Martínez Martínez, Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia, CSIC, Valencia, 46010 Spain

P074

Non-tuberculous mycobacteria

Detection of Mycobacterium avium subsp. paratuberculosis in fecal samples by culture in dairy farms in Panama

Fermin Acosta, Centro de Biología Celular y Molecular de Enfermedades, Instituto de Investigaciones Científicas y Servicios de Alta tecnología de Panamá (INDICASAT AIP), City of Knowledge, PANAMA

P075

Non-tuberculous mycobacteria

Genotyping of Mycobacterium leprae in humans and armadillos in a highly endemic area for leprosy in Brazil

Philip Noel Suffys, Laboratory of Molecular Biology Applied to Mycobacteria, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, Brazil

P076

Omics and modelling

From Research to Surveillance: Leveraging the State of Whole Genome Sequencing for Precision Public Health in a High-Burden Tuberculosis Setting

Emilyn Costa Conceicao, Instituto Evandro Chagas, Seção de Bacteriologia e Micologia, Ananindeua-PA, Brazil

P077

Omics and modelling

TOAST - A Tool for the design of targeted gene amplicons for the application of high throughput sequencing in genomic studies of tuberculosis

Linfeng Wang, London School of Hygiene and Tropical Medicine

P078

Host pathogen and vaccines

Analyzing the cell wall lipids of Bacillus Calmette Güerin (BCG) strains and pathogenic strains of the complex of Mycobacterium tuberculosis isolated from humans

Gloria Guillermina Guerrero Manriquez, University Autonomous of Zacatecas

P079

Diagnostics

Can Emergence of Canonical Mechanisms of Isoniazid Resistance in Tuberculosis Be Predicted?

Siavash Valafar, Chicago Medical School

P080

Omics and modelling

Predictive AI Models for Personalized Prognosis of Tuberculosis Treatment

Siavash Valafar, Chicago Medical School

P081

Diagnostics

Xpert MTB/XDR assay: Rapid TB drug resistance detection

Sunil Kumar Dhatwalia, Post Graduate Institute of Medical Education Research , Chandigarh

P082

Drug susceptibility testing

Susceptibility patterns of Mycobacterium avium complex isolates recovered in two Greek University Hospitals 

Fanourios Kontos, Laboratory of Clinical Microbiology, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

P083

Diagnostics

Broth microdilution plate-based minimal inhibitory concentration testing using MGIT-positive cultures

Praharshinie Rupasinghe, Institute of tropical medicine, Antwerp, Belgium

P084

TB treatment

Antimycobacterial activity of Bulgarian essential oils from Rosa species against reference and clinical Mycobacterium tuberculosis strains

Violeta Valcheva, Stephan Angeloff Institute of microbiology, Bulgarian Academy of Sciences

P085

Diagnostics

Reference-free clustering as an epidemiological tool for Mycobacterium tuberculosis strain typing

Aureliana Filomena Chambal Chilengue, Nottingham Trent University

P086

Diagnostics

Diagnostic accuracy of the LiquidArray MTB-XDR VER1.0 for the detection of Mycobacterium tuberculosis complex and fluoroquinolone, amikacin, ethambutol, and linezolid resistance

Margaretha de Vos, FIND, Geneva, Switzerland

P087

Non-tuberculous mycobacteria

NGS for the identification of less frequently encountered mycobacteria species in a clinical laboratory

Li-Hwei Sng, Singapore General Hospital

P088

Diagnostics

Pre-treat or Not pre-treat? Evaluation of DNA extraction pre-treatment procedures for Mycobacterium tuberculosis whole genome sequencing of clinical primary MGIT cultures

Emilyn Costa Conceicao, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

P089

Diagnostics

Whole genome sequencing analysis of M. tuberculosis from direct specimens: a hybrid capture approach

Godstime Stephen Kojo Morgan, San Raffael Scientific Institute

P090

Diagnostics

Whole genome sequencing analysis of M. tuberculosis from direct specimens: a hybrid capture approach

Godstime Stephen Kojo Morgan, San Raffael Scientific Institute

P091

TB treatment

The novel combination alpibectir/ethionamide (AlpE) is active on drug-sensitive and drug-resistant clinical isolates of Mycobacterium tuberculosis

Line Hofmann, Bioversys SAS

P093

Non-tuberculous mycobacteria

Evaluation of a new molecular diagnostic tool for the identification of NTM/MTB in positive MIGIT cultures

Sara Caldrer, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella (Verona), Italy

P094

Diagnostics

Excellent specificity and moderate to robust sensitivity of Xpert MTB/XDR for TB drug-susceptibility testing compared against Deeplex Myc-TB in nine African countries

Faridath Massou, Laboratoire de Référence de Mycobactéries, Cotonou, Benin

P095

Diagnostics

Preliminary study on STANDARD™ M10 MTB/NTM, a RT-PCR multiplex test for management of TB and NTM patients

Francesco Bisognin, Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy

P096

Diagnostics

Growth Units in the MGIT below the instrument threshold to call resistance may be predictive of Rv0678 conferring resistance mutations

Elisa Ardizzoni, Institute of Tropical Medicine of Antwerp

P097

Diagnostics

Collision of three global pandemics: the effect of tuberculosis and HIV on the epidemiological, clinical, virological, and immunological trajectory of Covid-19 in household contacts

Mareli Claassens, University of Namibia

P098

Diagnostics

Collision of three global pandemics: the effect of tuberculosis and HIV on the epidemiological, clinical, virological, and immunological trajectory of COVID-19 in Botswana and Namibia at primary healthcare facilities

Mareli Claassens, University of Namibia

P099

Diagnostics

Better care through better quality control: Why quality control of DNA libraries is crucial for real-time sequencing of clinical cultures

Felicia Wells, DST NRF Centre of Excellence for Biomedical Tuberculosis Research

P100

Diagnostics

Rapid and sensitive detection of viable mycobacteria in bovine faeces and blood by a novel phagomagnetic separation (PhMS)-qPCR assay

Irene Grant, Queen's University Belfast

P101

Diagnostics

Novel duplex qPCR and LAMP assays suitable for differentiating Mycobacterium bovis from other Mycobacterium tuberculosis complex species in MGIT sputum cultures

Irene Grant, School of Biological Sciences, Queen's University Belfast

P102

Diagnostics

Evaluation of the cobas® MTB Real-Time PCR plus MTB-RIF/INH assay in a low incidence country

Janina Koglin, MVZ Labor Limbach Heidelberg

P103

Diagnostics

Resolution of phylogenetic typing in Mycobacterium tuberculosis: a comparison between WGS and tNGS

Anzaan Dippenaar, University of Antwerp

P104

Drug susceptibility testing

Low pH, high-throughput assay as a clinically relevant screening effort in Mycobacterium tuberculosis (H37Rv)

Peggy Janssens, Johnson &Johnson

P105

Non-tuberculous mycobacteria

The upstream region of Mycobacterium abscessus whiB7 as a culprit for poor treatment outcome?

Nathan De Boeck, KU Leuven - Centre of Microbial and Plant Genetics

P106

Non-tuberculous mycobacteria

Dialysis waters: should we look for Mycobacteria?

Angela Cannas, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy

P107

Diagnostics

Optimization of Mycobacterial tuberculosis complex sample processing for whole genome sequencing

Noud Hermans, KNCV Tuberculosis Foundation

P108

Drug susceptibility testing

Phenotyping resistance to bedaquiline and emerging medicines assessment by a fast RNA-based drug susceptibility test: TRACeR-TB

Amandine Sury, Scientific Service Bacterial Diseases - Infectious Diseases in Humans, Sciensano, Brussels, Belgium

P109

Diagnostics

The first evaluation of targeted nanopore-based sequencing for tuberculosis drug resistance detection

Kiarash Moghaddasi, San Raffaele Scientific Institute

P110

Drug susceptibility testing

Emergence of bedaquiline resistance in drug-resistant tuberculosis samples from Mozambique

Tatiana Fernando, National Institute of Health (INS) Mozambique

P111

Diagnostics

Evaluation of sample pre-treatment protocols for detection of mycobacterial DNA directly in sputum samples

Michaela Jonsson Nordvall, Department of Clinical Microbiology, University Hospital, Linköping, Sweden

P112

Non-tuberculous mycobacteria

Clinical characteristics and treatment of non-tuberculous mycobacterial skin and soft tissue infections: a retrospective case series

Wouter Peeters, Radboud University Medical Center

P113

Diagnostics

Validating the second edition of the WHO tuberculosis resistance catalogue using GPAS, a cloud platform for processing pathogen genetic data

Philip Fowler, University of Oxford

P114

Non-tuberculous mycobacteria

Non-tuberculous mycobacteria among previously treated tuberculosis patients with microscopy-positive and Xpert-negative results in Niger

Mahamadou Bassirou Souleymane Tiemogo, University of Antwerp, Department of Biomedical Sciences, Antwerp, Belgium

P115

Non-tuberculous mycobacteria

Non-tuberculous mycobacteria isolated at the end of the world

Ximena Ferrara, Instituto de Agrobiotecnología y Biotecnología Molecular (IABIMO), UEDD INTA-CONICET; CICVyA, Instituto Nacional de Tecnología Agropecuaria, Buenos Aires, Argentina

P116

Drug susceptibility testing

Deeplex® Myc-TB assay: Informing genotypic/phenotypic associations in Mycobacterium tuberculosis isolates

Melanie Grobbelaar, Faculty of Medicine and Health Sciences, Stellenbosch University

P117

Diagnostics

Investigating the resistance rate and transmission of Mycobacterium abscessus among cystic fibrosis and non-cystic fibrosis patients

Erik Michael Rasmussen, Biomedical Centre Martin, Jessenius Faculty of Medicine in Martin, Comenius University, Bratislava, Slovakia

P118

Drug susceptibility testing

DprE1 inhibitors and bedaquiline combination for the treatment of TB: in vitro effect on MIC of susceptible and resistant M. tuberculosis strains

Andrea Muscetti, San Raffaele Scientific Institute

P119

Diagnostics

Tuberculosis screening among migrants: a qualitative study on healthcare seeking behaviour and acceptance of tongue swabs 

Francesca Saluzzo, Universita Vita-Salute San Raffaele

P120

Non-tuberculous mycobacteria

Possible host genetic factors influencing leprosy susceptibility in a multiplex family from Anjouan, Comoros

Lena Kraußer, Institute of Tropical Medicine (ITM), Antwerp, Belgium

P121

Other

Comparison of DRB3.2 alleles among false-negative and positive tuberculin skin test cattle with bovine tuberculosis

Ximena Ferrara, Instituto de Agrobiotecnología y Biotecnología Molecular (IABIMO), UEDD INTA-CONICET; CICVyA, Instituto Nacional de Tecnología Agropecuaria

P122

Other

70 % ethanol preserves mycobacterial RNA from culture more efficiently than GTC-TCEP

Lena Kraußer, Institute of Tropical Medicine (ITM), Antwerp, Belgium

P123

Diagnostics

Demonstration of targeted next-generation sequencing using the Oxford Nanopore Technologies tuberculosis assay for the detection of drug resistant tuberculosis in Kyrgyzstan

Kristin Kremer, KNCV Tuberculosis Foundation, The Hague, The Netherlands

P124

Drug susceptibility testing

Establishing of drug susceptibility testing to Pretomanid

Elvira Richter, Labor Limbach

P125

Diagnostics

Experiences from a demonstration study on Nanopore sequencing for the diagnosis of drug-resistant tuberculosis in low-middle-income countries

Kristin Kremer, KNCV Tuberculosis Foundation, The Hague, The Netherlands

P126

Diagnostics

Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis

Maria Teresa Tórtola Fernández, Microbiology Service. Hospital University Vall d’Hebron

P127

Drug susceptibility testing

Using targeted Next Generation Sequencing directly from sputum for comprehensive drug resistance prediction of Mycobacterium tuberculosis strains in Namibia

Lusia Mhuulu, Department of Human, Biological & Translational Sciences, School of Medicine, University of Namibia, Namibia

P128

Diagnostics

GPAS pipeline relatedness service for TB

Derrick William Crook, The University of Oxford

P129

Drug susceptibility testing

BTZ-043 exposure in vitro selects efflux pump mutants and BTZ-043, bedaquiline and clofazimine resistance in Mycobacterium tuberculosis

Arash Ghodousi, Vita-Salute San Raffaele University

P130

Drug susceptibility testing

Clusters of intrinsically delamanid/pretomanid cross-resistant strains of Mycobacterium tuberculosis in eastern Europe and central Asia

Kurt Wollenberg, National Institute of Allergy and Infectious Diseases

P131

TB treatment

Cathelidicin, Vitamin D isoforms levels during the first month of anti-tuberculosis therapy

Fermin Acosta, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología, Ciudad del Saber, Panamá

P132

Diagnostics

Acceptance of oral swabs for tuberculosis screening among healthcare workers: a qualitative study

Renee Codsi, Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, WA, 98195, USA

P133

Diagnostics

Routine investigations for tuberculosis on bronchoalveolar fluid lavage in a low-incidence setting: is it worth it?

Chiara Sepulcri, Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genova, 16132 Genova, Italy

P134

Diagnostics

LiquidArray MTB-XDR VER 1.0 - a powerful molecular genetic tool for rapid diagnosis of extensively drug-resistant tuberculosis

Vera Allerheiligen, Bruker-Hain

P135

Diagnostics

LiquidArray® Mycobacteria direct: Detection of MTBC and NTM directly from patient specimens

Vera Allerheiligen, Bruker-Hain

P136

Diagnostics

Analytical and Clinical performance evaluation of the FluoroType® MTBDR VER 2.0 with Dual Target Detection of Mycobacterium tuberculosis Complex from Native Sputum and Culture

Vera Allerheiligen, Bruker-Hain

P137

Non-tuberculous mycobacteria

Whole Genome Sequence of Mycolicibacterium parafortuitum Panama NTM 1 isolated from a cattle farm in Panama

Fermin Acosta, Centro de Biología Molecular y Celular de Enfermedades, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT-AIP); Ciudad del Saber, Panamá.

bottom of page